This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Headquartered in Deerfield, IL, Baxter International Inc. (BAX) is a global medical technology company. However, the company spun off its biopharmaceuticals segment into an independent entity – Baxalta Inc. Following the spinoff, the company consists of renal and hospital products, providing items such as kidney-dialysis equipment, infusion pumps, and intravenous (IV) solutions.
Zacks.com highlights: Chemed, Baxter International, IDEXX Laboratories, Advanced Energy Industries and Pioneer Natural Resources
by Zacks Equity Research
Zacks.com highlights: Chemed, Baxter International, IDEXX Laboratories, Advanced Energy Industries and Pioneer Natural Resources
5 of the Most Efficient Stocks to Boost Your Portfolio
by Tirthankar Chakraborty
Company with a favorable efficiency level generally provides impressive returns as it is believed to be positively correlated with the stock's price performance.
The Zacks Analyst Blog Highlights: Baxter International, BostonScientific, Intuitive Surgical and Becton and Dickinson
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Baxter International, BostonScientific, Intuitive Surgical and Becton and Dickinson
Trump Focuses on APAC: 4 MedTech Stocks to Watch
by Zacks Equity Research
Considering Trump's growing focus on APAC, the region seems to be poised to yield accretive returns over the long term. Favorable MedTech trends in APAC hold promise.
Baxter International (BAX) Beats on Earnings And Sales in Q3
by Zacks Equity Research
Baxter's (BAX) adjusted earnings of 64 cents per share beat the Zacks Consensus Estimate of 59 cents and increased by 8 cents from the year-ago quarter.
MedTech Stocks (BAX, VAR, TMO, LH) Earnings Preview: What You Should Know
by Zacks Equity Research
The Medical Product space has been a precarious game for the Republicans since day one, courtesy of President Trump's repeated failure to repeal and replace Obamacare.
Baxter International (BAX) Q3 Earnings: What's in Store?
by Zacks Equity Research
Baxter International Inc's (BAX) third quarter estimate revision trend is encouraging due to acquisitions and strategic collaborations to enhance its product portfolio.
Baxter Announces Launch of DeviceVue System for Sigma Pumps
by Zacks Equity Research
Baxter's (BAX) latest development is expected to fortify its foothold in the smart pumps market.
Baxter (BAX) Hits a 52-Week High: What's Driving the Stock?
by Zacks Equity Research
Baxter (BAX) reaches a 52-week high on the back of an impressive product line. Buoyed by last quarter's stellar growth in earnings and sales, the company also raises long-term outlook.
NxStage Medical Partners Dialyze Direct for On-Site Dialysis
by Zacks Equity Research
The latest development will lend NxStage Medical (NXTM) a competitive edge in the hemodialysis dialysis market. The company will leverage on its System One platform for treating patients with ESRD.
Baxter (BAX) Beats on Q2 Earnings, Raises Long-Term Outlook
by Zacks Equity Research
Baxter International (BAX) delivered a solid second quarter driven by favorable tidings on the regulatory front, strategic partnerships and product launches.
Baxter International (BAX) Beats on Earnings And Sales in Q2
by Zacks Equity Research
Baxter's adjusted earnings of 63 cents per share beat the Zacks Consensus Estimate of 57 cents and increased by 17 cents from the year-ago quarter.
Baxter International (BAX) Q2 Earnings: What's in Store?
by Zacks Equity Research
Despite an upbeat guidance, lower cyclophosphamide sales are likely to mar Baxter International (BAX) performance in the second quarter 2017.
3 Excellent Value Picks Amid Political Grind in MedTech
by Zacks Equity Research
While the revised American Health Care Act now only needs the Senate's nod, the scenario is getting increasingly challenging for the Medical Device Space.
Baxter and TAU Ink New Licensing Agreements through Ramot
by Zacks Equity Research
Baxter International (BAX) has recently teamed up with Tel Aviv University, Israel's largest research and teaching university (TAU), on two new licensing agreements through Ramot.
Zacks.com featured highlights: American Woodmark, Lantheus Holdings, Baxter International, Apogee Enterprises and MAM Software Group
by Zacks Equity Research
Zacks.com featured highlights: American Woodmark, Lantheus Holdings, Baxter International, Apogee Enterprises and MAM Software Group
Baxter (BAX) Scales 52-Week High: What's Behind the Rally
by Zacks Equity Research
Baxter International Inc. (BAX) scaled a new 52-week high of $60.47 on Jun 21, closing a bit lower at $60.05.
2 Solid Medical Device Stocks to Scoop Up Right Away
by Zacks Equity Research
Let's focus on two medical device stocks which will make valuable additions to an investment portfolio in the wake of widespread volatility in the medical device market.
Weakness Seen in Enzymotec (ENZY) Estimates: Should You Stay Away?
by Zacks Equity Research
Enzymotec (ENZY) has witnessed a significant price decline in the past four weeks, and is seeing negative earnings estimate revisions as well.
5 Top Performing Efficient Stocks to Buy Now
by Tirthankar Chakraborty
A favorable efficiency level provides impressive returns as it is positively correlated with the company's price performance
3 Medical Device Stocks with Solid Potential to Buy Now
by Zacks Equity Research
The Medical Device industry has been riding high on optimism of late, courtesy of the Senate's latest decision to lacerate the Affordable Care Act (ACA) by the end of July.
Baxter International (BAX) Up 6.7% Since Earnings Report: Can It Continue?
by Zacks Equity Research
Baxter International (BAX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks.com featured highlights: Baxter International, Lantheus Holdings, OraSure Technologies, MAM Software Group and Teradyne
by Zacks Equity Research
Zacks.com featured highlights: Baxter International, Lantheus Holdings, OraSure Technologies, MAM Software Group and Teradyne
Quest Diagnostics Poised on Solid Q1 Results Despite Woes
by Zacks Equity Research
On May 22, we issued an updated research report on Quest Diagnostics, Inc. (DGX), a major commercial laboratory services provider.
Medtronic (MDT) RESOLUTE ONYX Meets Primary Study Endpoint
by Zacks Equity Research
Medtronic plc (MDT) recently announced favorable outcome on its Resolute Onyx Drug-Eluting Stent.